Skip to content

Study · Observational study · 2010

2 results

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

Garg R, Chen W, Pendergrass M

Diabetes care3 Aug 2010Cited by 237 (Europe PMC)

PMID20682680 (opens in a new tab)PMCIDPMC2963493 (opens in a new tab)DOI10.2337/dc10-0482 (opens in a new tab)PepBankPUB-20682680
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studySafety outcome

    In a claims cohort, acute pancreatitis incidence among exenatide users was 5.7 cases per 1,000 patient years.

    In plain wordsIn a claims study, exenatide users had 5.7 acute pancreatitis cases per 1,000 patient years.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableAcute pancreatitis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Acute pancreatitis incidence
    5.7 cases per 1,000 patient years
    exenatide group

    Source sentences

    Summary
    Incidence of acute pancreatitis in the nondiabetic control group, diabetic control group, exenatide group, and sitagliptin group was 1.9, 5.6, 5.7, and 5.6 cases per 1,000 patient years, respectively.
    2 context sentences
    Summary · context
    A retrospective cohort study of a large medical and pharmacy claims database was performed.
    Summary · context
    Cox proportional hazard models were built to compare the risk of acute pancreatitis between diabetic and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication use.
  2. 02HumanObservational studySafety outcome

    In a claims cohort, exenatide use was not linked to significantly different acute pancreatitis risk versus diabetic control medication use.

    In plain wordsIn a claims study, exenatide use was linked to similar pancreatitis risk compared with other diabetes medication use.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAcute pancreatitis
    Study

    n: not reported in source

    Comparator
    Diabetic control medication users
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Acute pancreatitis risk estimate
    0.9 ratio
    exenatide versus diabetic controls
    Risk interval lower bound
    0.6 ratio
    exenatide versus diabetic controls
    Risk interval upper bound
    1.5 ratio
    exenatide versus diabetic controls

    Source sentences

    Summary
    Risk of acute pancreatitis was similar in the exenatide versus diabetic control group (0.9 [0.6-1.5]) and sitagliptin versus diabetic control group (1.0 [0.7-1.3]).
    2 context sentences
    Summary · context
    A retrospective cohort study of a large medical and pharmacy claims database was performed.
    Summary · context
    Cox proportional hazard models were built to compare the risk of acute pancreatitis between diabetic and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication use.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.